Skip to content

Study · Animal study (in vivo) · rabbit · 2019

10 results

Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.

Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, Lanske B

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA3 May 2019Cited by 23 (Europe PMC)

PMID31053927 (opens in a new tab)PMCIDPMC6663928 (opens in a new tab)DOI10.1007/s00198-019-04999-4 (opens in a new tab)PepBankPUB-31053927
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed vertebral areal BMD deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved vertebral bone density compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral areal BMD
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed proximal femoral areal BMD deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved proximal femoral bone density compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseProximal femoral areal BMD
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed femoral cortical area deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved femoral cortical area compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral diaphyseal cortical area
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed femoral cortical thickness deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved femoral cortical thickness compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral diaphyseal cortical thickness
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed femoral cortical volumetric BMD deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved femoral cortical bone density compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral diaphyseal volumetric BMD
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed vertebral and distal femoral trabecular bone volume deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved vertebral and distal femoral trabecular bone volume compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral and distal femoral trabecular bone volume
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide reversed vertebral and distal femoral trabecular volumetric BMD deficits compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved vertebral and distal femoral trabecular bone density compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral and distal femoral trabecular volumetric BMD
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    3 context sentences
    Summary · context
    GC-OVX rabbits showed significant deficits in vertebral and proximal femur areal BMD, lower cortical area, thickness and volumetric BMD of the femur diaphysis, and reduced trabecular bone volume and volumetric BMD in the vertebra and distal femur versus sham controls.
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, abaloparatide enhanced trabecular microarchitecture compared with GC-OVX controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, abaloparatide improved trabecular bone structure compared with GC-OVX controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableTrabecular microarchitecture
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    GC-OVX vehicle controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    These deficits were significantly reversed in the ABL25 group, which also showed enhanced trabecular micro-architecture versus GC-OVX controls.
    2 context sentences
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, femoral diaphyseal ultimate load with abaloparatide was similar to sham controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, femoral load tolerance with abaloparatide was similar to sham controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral diaphyseal ultimate load
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    Sham controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    Destructive bending tests showed significantly lower femur diaphysis ultimate load and bending rigidity of the femoral diaphysis in the GC-OVX group versus sham controls, whereas these parameters were similar in the ABL25 group vs sham controls.
    2 context sentences
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In glucocorticoid-challenged ovariectomized rabbits, femoral diaphyseal bending rigidity with abaloparatide was similar to sham controls.

    In plain wordsIn ovariectomized rabbits given glucocorticoids, femoral bending rigidity with abaloparatide was similar to sham controls.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral diaphyseal bending rigidity
    Study

    rabbitn = 16

    Ovariectomized rabbits with glucocorticoid-induced osteopenia
    Comparator
    Sham controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 12 weeksAs given in this study (rabbit).

    Source sentences

    Summary
    Destructive bending tests showed significantly lower femur diaphysis ultimate load and bending rigidity of the femoral diaphysis in the GC-OVX group versus sham controls, whereas these parameters were similar in the ABL25 group vs sham controls.
    2 context sentences
    Summary · context
    This study assessed abaloparatide effects on BMD and bone strength in ovariectomized (OVX) rabbits with glucocorticoid (GC)-induced osteopenia.
    Summary · context
    GC-challenged rabbits (8/group) then received GC (0.5 mg/kg/day) along with daily s.c. vehicle (GC-OVX), abaloparatide 5 μg/kg/day (ABL5), or 25 μg/kg/day (ABL25) for 12 weeks, and the no-GC OVX and sham controls received daily vehicle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.